SciELO - Scientific Electronic Library Online

 
vol.10 número1Chondromyxoid fibroma: a case series and radiological reviewTraumatic dislocation of the hip joint in children índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • En proceso de indezaciónSimilares en Google

Compartir


SA Orthopaedic Journal

versión On-line ISSN 2309-8309
versión impresa ISSN 1681-150X

Resumen

MUNTINGH, GL. Do some of the newer COX-2 inhibitors cross-react with sulfonamide antibiotics? An overview. SA orthop. j. [online]. 2011, vol.10, n.1, pp.73-76. ISSN 2309-8309.

The professional information leaflets of three locally available specific cyclooxygenase-2 inhibitors indicate that these drugs are contraindicated in persons with a known allergy to sulfonamides. There are many concerns about cross-allergenicity between sulfonamide antibiotics and non-antibiotic sulfonamide-containing drugs including the sulfones, and these concerns continue to complicate drug therapy. Several elegant investigations have demonstrated lack of interaction between the sulfonamide group and either cellular or humoral immunity. The immunologic determinant of type I immunologic responses to sulfonamide antibiotics are the N1 heterocyclic ring, and non-antibiotic sulfonamides including the sulfones lack this structural feature. Reactive sulfonamide metabolites contribute many non-type I hypersensitivity responses to sulfonamide antibiotics. Metabolite formation demonstrates stereospecificity to the N4 amino nitrogen of the sulfonamide antibiotics, a structure not found on any non-antibiotic sulfonamide drugs and is also lacking in the sulfones. Apparent cross-reactivity responses to sulfonamide-containing drugs likely represent multiple concurrent, rather than linked, drug hypersensitivities.

        · texto en Inglés     · Inglés ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons